CLEARSIDE BIOMEDICAL INC (CLSD) Stock Price, Quote, News and Overview
NASDAQ:CLSD - Nasdaq - US1850631045 - Common Stock - Currency: USD
CLSD Quote, Performance and Key Statistics
0.95
-0.08 (-7.77%)
The current stock price of CLSD is 0.95 USD. In the past month the price increased by 1.8%. In the past year, price decreased by -30.15%.
CLSD Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About CLSD
Company Profile
Clearside Biomedical, Inc. is a biopharmaceutical company, which delivers therapies to the back of the eye through the suprachoroidal space. The company is headquartered in Alpharetta, Georgia and currently employs 30 full-time employees. The company went IPO on 2016-06-02. The firm's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The firm is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The firm's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. The company developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner.
Company Info
CLEARSIDE BIOMEDICAL INC
900 North Point Parkway, Suite 200
Alpharetta GEORGIA 30005 US
CEO: George Lasezkay
Employees: 30
Company Website: https://clearsidebio.com/
Investor Relations: http://ir.clearsidebio.com/investor-overview
Phone: 16782703631
CLEARSIDE BIOMEDICAL INC / CLSD FAQ
What is the stock price of CLEARSIDE BIOMEDICAL INC today?
The current stock price of CLSD is 0.95 USD. The price decreased by -7.77% in the last trading session.
What is the ticker symbol for CLEARSIDE BIOMEDICAL INC stock?
The exchange symbol of CLEARSIDE BIOMEDICAL INC is CLSD and it is listed on the Nasdaq exchange.
On which exchange is CLSD stock listed?
CLSD stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CLEARSIDE BIOMEDICAL INC stock?
13 analysts have analysed CLSD and the average price target is 6.12 USD. This implies a price increase of 544.21% is expected in the next year compared to the current price of 0.95. Check the CLEARSIDE BIOMEDICAL INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CLEARSIDE BIOMEDICAL INC worth?
CLEARSIDE BIOMEDICAL INC (CLSD) has a market capitalization of 72.05M USD. This makes CLSD a Micro Cap stock.
How many employees does CLEARSIDE BIOMEDICAL INC have?
CLEARSIDE BIOMEDICAL INC (CLSD) currently has 30 employees.
What are the support and resistance levels for CLEARSIDE BIOMEDICAL INC (CLSD) stock?
CLEARSIDE BIOMEDICAL INC (CLSD) has a support level at 0.92 and a resistance level at 0.95. Check the full technical report for a detailed analysis of CLSD support and resistance levels.
Is CLEARSIDE BIOMEDICAL INC (CLSD) expected to grow?
The Revenue of CLEARSIDE BIOMEDICAL INC (CLSD) is expected to decline by -75.4% in the next year. Check the estimates tab for more information on the CLSD EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CLEARSIDE BIOMEDICAL INC (CLSD) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CLSD, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CLSD, evaluating the profitability, health, valuation and growth aspects
- CLEARSIDE BIOMEDICAL INC (CLSD) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CLEARSIDE BIOMEDICAL INC (CLSD) Sales and EPS estimates to see what analysts future expectations are.
- CLEARSIDE BIOMEDICAL INC (CLSD) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CLEARSIDE BIOMEDICAL INC (CLSD) Insider and Institutional Ownership to learn about the owners and their transactions.
- CLEARSIDE BIOMEDICAL INC (CLSD) Stock Chart to make your own analysis
- CLEARSIDE BIOMEDICAL INC (CLSD) Latest news and press-releases to stay up to date.
Does CLEARSIDE BIOMEDICAL INC (CLSD) stock pay dividends?
CLSD does not pay a dividend.
When does CLEARSIDE BIOMEDICAL INC (CLSD) report earnings?
CLEARSIDE BIOMEDICAL INC (CLSD) will report earnings on 2025-03-18, after the market close.
What is the Price/Earnings (PE) ratio of CLEARSIDE BIOMEDICAL INC (CLSD)?
CLEARSIDE BIOMEDICAL INC (CLSD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.43).
What is the Short Interest ratio of CLEARSIDE BIOMEDICAL INC (CLSD) stock?
The outstanding short interest for CLEARSIDE BIOMEDICAL INC (CLSD) is 1.11% of its float. Check the ownership tab for more information on the CLSD short interest.
CLSD Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to CLSD. When comparing the yearly performance of all stocks, CLSD is a bad performer in the overall market: 85.68% of all stocks are doing better.
CLSD Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CLSD. CLSD may be in some trouble as it scores bad on both profitability and health.
CLSD Financial Highlights
Over the last trailing twelve months CLSD reported a non-GAAP Earnings per Share(EPS) of -0.43. The EPS increased by 29.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -109.31% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CLSD Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to CLSD. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of 10.1% and a revenue growth -75.4% for CLSD